Efficacy of colesevelam on lowering glycemia and lipids

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011 · see citing works

Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association

Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., Ford, E. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182009701 · Cited by 6,149 · see citing works

Heart Disease and Stroke Statistics—2009 Update

WRITING GROUP MEMBERS, Lloyd‐Jones, D. M., Adams, R. J., Carnethon, M. R., SIMONE, G. D., Ferguson, T. B., Flegal, K. M., Ford, E. S., Furie, K. L., Go, A. S., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191259 · Cited by 3,891 · see citing works

Heart Disease and Stroke Statistics—2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191261 · Cited by 3,140 · see citing works

Major lipids, apolipoproteins, and risk of vascular disease

The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731 · see citing works

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678 · see citing works

Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies

Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · see citing works

Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue

Laffitte, B. A., Chao, L. C., Li, J., Walczak, R., Hummasti, S., Joseph, S. B., Castrillo, A., Wilpitz, D. C., Mangelsdorf, D. J., Collins, J. L., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830671100 · Cited by 503 · see citing works

Colesevelam Hydrochloride (Cholestagel): A New, Potent Bile Acid Sequestrant Associated With a Low Incidence of Gastrointestinal Side Effects

Davidson, M. H., Dillon, M. A., Gordon, B., Jones, P., Samuels, J., Weiss, S., Isaacsohn, J., Toth, P., & Burke, S. K. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.16.1893 · Cited by 307 · see citing works

Antidiabetic Action of a Liver X Receptor Agonist Mediated By Inhibition of Hepatic Gluconeogenesis

Cao, G., Yu, L., Broderick, C. L., Oldham, B. A., Beyer, T., Schmidt, R. J., Zhang, Y., Stayrook, K. R., Suen, C. S., Otto, K. A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210208200 · Cited by 298 · see citing works

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy

Fonseca, V. A., Rosenstock, J., Wang, A. C., Truitt, K. E., & Jones, M. R. (2008) · Diabetes Care · doi:10.2337/dc08-0283 · Cited by 243 · see citing works

Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes

Zieve, F. J., Kalin, M. F., Schwartz, S. L., Jones, M. R., & Bailey, W. L. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.003 · Cited by 216 · see citing works

Colesevelam Hydrochloride Therapy in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Bays, H. E., Goldberg, R. B., Truitt, K. E., & Jones, M. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.18.1975 · Cited by 212 · see citing works

Colestipol hydrochloride in hypercholesterolemic patients—Effect on serum cholesterol and mortality

Dorr, A. E., Gundersen, K., Schneider, J. C., Spencer, T. W., & Martin, W. B. (1978) · Journal of Chronic Diseases · doi:10.1016/0021-9681(78)90076-0 · Cited by 203 · see citing works

Efficacy and Safety of Colesevelam in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Receiving Insulin-Based Therapy

Goldberg, R. B. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.14.1531 · Cited by 194 · see citing works

Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease.

Pocock, S., Shaper, A. G., & Phillips, A. N. (1989) · BMJ · doi:10.1136/bmj.298.6679.998 · Cited by 147 · see citing works

Effectiveness of Colesevelam Hydrochloride in Decreasing LDL Cholesterol in Patients With Primary Hypercholesterolemia: A 24-Week Randomized Controlled Trial

Insull, W., Toth, P. D., Mullican, W. S., Hunninghake, D. B., Burke, S. K., Donovan, J. M., & Davidson, M. H. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.10.971 · Cited by 138 · see citing works

Liver X Receptor Activation Stimulates Insulin Secretion via Modulation of Glucose and Lipid Metabolism in Pancreatic Beta-Cells

Efanov, A. M., Sewing, S., Bokvist, K. B., & Gromada, J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s75 · Cited by 135 · see citing works

Colesevelam HCl: a non-systemic lipid-altering drug

Bays, H. E., & Dujovne, C. A. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.779 · Cited by 98 · see citing works

Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the framingham offspring study

Wilson, P. W. F., Anderson, K. M., Castelli, W. P., & Kannel, W. B. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90500-w · Cited by 93 · see citing works

A Multicenter Comparison of Lovastatin and Cholestyramine Therapy for Severe Primary Hypercholesterolemia

(1988) · JAMA · doi:10.1001/jama.1988.03410030075032 · Cited by 93 · see citing works

A Review of Bile Acid Sequestrants: Potential Mechanism(s) for Glucose-Lowering Effects in Type 2 Diabetes Mellitus

Staels, B. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.suppl53.290 · Cited by 54 · see citing works

Absorption of Colesevelam Hydrochloride in Healthy Volunteers

Heller, D. P., Burke, S. K., Davidson, D. M., et al. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a143 · Cited by 42 · see citing works

Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway

Goldfine, A. B. (2008) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32830c6c37 · Cited by 41 · see citing works

Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes

Goldfine, A. B., Fonseca, V. A., Jones, M. R., Wang, A. C., Ford, D. M., & Truitt, K. E. (2009) · Hormone and Metabolic Research · doi:10.1055/s-0029-1241195 · Cited by 40 · see citing works

Choosing the Right Lipid-Regulating Agent

Farmer, J. A., & Gotto, A. M. (1996) · Drugs · doi:10.2165/00003495-199652050-00003 · Cited by 40 · see citing works

Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia

Rosenson, R. S. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.05.032 · Cited by 39 · see citing works

Effects of Colesevelam Hydrochloride (WelChol) on Biomarkers of Inflammation in Patients With Mild Hypercholesterolemia

Devaraj, S., Autret, B. C., & Jialal, I. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.03.043 · Cited by 39 · see citing works

Concomitant Reduction in Low-Density Lipoprotein Cholesterol and Glycated Hemoglobin With Colesevelam Hydrochloride in Patients With Type 2 Diabetes: A Pooled Analysis

Jialal, I., Abby, S. L., Misir, S., & Nagendran, S. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2009.0007 · Cited by 33 · see citing works

Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol

Corsini, A., Windier, E. T. E., & Farnier, M. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32831215db · Cited by 30 · see citing works

Effects of colesevelam on LDL‐C, A1c and GLP‐1 levels in patients with type 1 diabetes: a pilot randomized double‐blind trial

Garg, S. K., Ritchie, P. J., Moser, E. G., Snell‐Bergeon, J. K., Freson, B. J., & Hazenfield, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01320.x · Cited by 30 · see citing works

Absorption, Distribution and Excretion of GT31-104, a Novel Bile Acid Sequestrant, in Rats and Dogs After Acute and Subchronic Administration

Rosenbaum, D. P., Petersen, J. S., Ducharme, S., Markham, P. M., & Goldberg, D. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js9603820 · Cited by 27 · see citing works

Colestipol Hydrochloride, a New Hypolipidemic Drug

Cooper, E. E., & MICHEL, A. M. (1975) · Southern Medical Journal · doi:10.1097/00007611-197503000-00011 · Cited by 20 · see citing works

Colesevelam hydrochloride powder for oral suspension versus cholestyramine powder for oral suspension: comparison of acceptability and tolerability.

Bays, H., Maki, K., & Schmitz, K. (2011) · Endocrine Practice · doi:10.4158/ep10251.or · Cited by 7 · see citing works

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary

Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598 · see citing works

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M. B., Orringer, C. E., & Smith, S. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.519 · Cited by 459 · see citing works

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435 · see citing works

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297 · see citing works

Insulin resistance is associated with hypertriglyceridemia and combined hyperlipidemia but not with hypercholesterolemia in familial combined hyperlipidemia

Pihlajamäki, J., Karjalainen, L., & Laakso, M. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)80041-0

[Hyperlipidemia in uremic patients in dialysis].

Docci, D., Bilancioni, R., Turci, F., et al. (1985) · PubMed · Cited by 2 · see citing works

Effect of Qihuang Decoction on Serum Lipid of Hyperlipidemia Rats

Xu, A. (2007)

THERAPEUTIC EFFECT OF MORTIERELLA ISABELLINA EXTRACTS ON HYPERLIPIDEMIA

Li, M. (2004) · Chinese Journal of Appplied Environmental Biology

Antibodies against high-density lipoprotein binding proteins enhance high-density lipoprotein uptake but do not affect cholesterol efflux from rat hepatoma cells

Sviridov, D., Sasahara, T., Pyle, L. E., et al. (1997) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(96)00174-4 · Cited by 20 · see citing works